Adverse Outcomes 30 Days After Emergency Department Evaluation for Myocardial Infarction Determined Solely by High Sensitivity Troponin I Values for a 1-Hour Rule-Out/Rule-In Acute Myocardial Infarction Algorithm
Recommended Citation
Nowak RM, McCord J, Christenson RH, Jacobsen G, Apple F, Limkakeng A, Peacock WF, and DeFilippi C. 5 Adverse Outcomes 30 Days After Emergency Department Evaluation for Myocardial Infarction Determined Solely by High Sensitivity Troponin I Values for a 1-Hour Rule-Out/Rule-In Acute Myocardial Infarction Algorithm. Ann Emerg Med 2019; 74(4):S3.
Document Type
Conference Proceeding
Publication Date
10-2019
Publication Title
Ann Emerg Med
Abstract
Study Objectives: High sensitivity cardiac troponin I (hs-cTnI) rapid evaluations for acute myocardial infarction (AMI) are being approved/used in the United States (US). Our objective was to determine the efficacy of the 1-hour AMI rule-out/rule-in hs-cTnI algorithm zone placements for all enrolled patients in the High Sensitivity Cardiac Troponin I in the US (HIGH-US) study for determining 30-day adverse outcomes. Methods: This was a secondary analysis of a prospective multi-center observational study (HIGH-US). Consenting adults presenting with any suspicion by the treating emergency physician for AMI were enrolled. The baseline and 1-hour plasma samples obtained were later batch analyzed in 5 core laboratories using the Siemens Atellica hs-cTnI assay (combined sex 99th % 45.0 ng/L). AMI diagnosis was independently adjudicated using all 30-day clinical materials available. All enrolled subjects were followed up at 30 days by telephone and review of their medical records. Adverse outcomes reported are all cause death and post discharge AMI. Results: A total of 2505 patients were enrolled in 29 US medical centers with 2113 qualifying for a validation of the 1-hour algorithm. Subject median age was 56 years (interquartile range 48-65), 1313 (56.0%) were males with 1313 (56.0%) white and 939 (40.0%) black patients. There were 1065 (50.4%) patients ruled-out with a NPV of 99.7% and sensitivity of 98.7% (95% CI: 99.2-99.9 and 96.3-99.6 respectively) using a baseline hs-cTnI value < 3ng/L or baseline value < 6ng/L and a delta 1 hour value < 3ng/L. Additionally there were 265 (12.6%) individuals ruled-in with a PPV of 69.4% and specificity of 95.7% (95% CI: 63.6-74.7 and 94.7-96.5 respectively) using a baseline hs-cTnI value > 120 ng/L or a delta 1 hour value ≥ 12ng/L. The remaining 783 (37.1%) patients placed in the continue evaluations zone had a prevalence of adjudicated AMI of 5.6% (95% CI 4.2-7.5). The 30-day rate of death or AMI was low (2, 0.02%) for ruled-out patients, higher (16, 2.1%) for those placed in the continued evaluations zone and highest (13, 4.8%) for ruled-in subjects (p
Volume
74
Issue
4
First Page
S3
